作为项目负责人曾主持国家自然科学基金2项、北京市自然科学基金面上项目2项、中国博士后基金1项，北京市医院管理中心科研培育课题1项，北京市科协金桥工程种子资金2项。现主持中国高校产学研创新基金、北京市自然科学基金-昌平创新联合基金、北京市卫健委首都医学科技创新成果转化优促计划赋能项目、国家卫健委药政司国家基本药物中药饮片配备使用政策研究项目、国家卫生健康委医院管理研究所医疗质量循证管理持续改进重大项目、国家卫生健康委医院管理研究所医院药学高质量发展重点项目、北京市呼吸疾病研究所院所融合发展项目、北京朝阳医院科创基金等科研项目。

入选北京市卫健委高层次公共卫生技术人才建设项目、北京市医管中心青苗人才培养项目、中国药学会医院药学专委会医院药学优秀人才项目、中国药学会施维雅青年医院药学奖、北京朝阳医院1351人才培养项目。

近五年作为第一作者/共同一作或独立通讯作者发表 SCI 论文64篇，合计影响因子 287.75，单篇最高影响因子12.70。

申报专利19项（第一发明人申报9项），其中作为第一发明人已获得专利授权5项。

1.  Yang H, Wang Z, Jiang C, ZhangY, Zhang Y, Xu M, Zhang Y, Wang Y, Liu X, An Z*, Tong Z*. Oral azvudinefor mild-to-moderate COVID-19 in high risk, nonhospitalized adults: Results ofa real-world study. J Med Virol. 2023 Jul;95(7):e28947. doi: 10.1002/jmv.28947.   （IF:12.7）    

2.  Yang H*, Wang Z*, Zhang Y, XuM, Wang Y, Zhang Y, Liu X, An Z*, Tong Z*. Clinical characteristics andfactors for serious outcomes among outpatients infected with the Omicronsubvariant BF.7. J Med Virol. 2023 Aug;95(8):e28977. doi: 10.1002/jmv.28977.        （IF:12.7）    

3.  Wang X, Ye Z, Busse JW, HillMD, Smith EE*, Guyatt GH, Prasad K, Lindsay MP, Yang H, Zhang Y, Liu Y, Tang B,Wang X, Wang Y, Couban RJ, An Z*. Endovascular thrombectomy with orwithout intravenous alteplase for acute ischemic stroke due to large vesselocclusion: a systematic review and meta-analysis of randomized trials. StrokeVasc Neurol. 2022 Jun 20:svn-2022-001547. doi: 10.1136/svn-2022-001547.     （IF:9.893）  

4. Xuan L, Ren L, Zhang W, Du P,Li B, An Z*. Formaldehyde aggravates airway inflammation throughinduction of glycolysis in an experimental model of asthma exacerbated bylipopolysaccharide. Sci Total Environ. 2024 Feb 20;912:168947. doi:10.1016/j.scitotenv.2023.168947.    （IF:9.8）      

5.  Zhao R#, An Z#, Sun Y,Xia L, Qiu L, Yao A, Liu Y*, Liu L*. Metabolic profiling in early pregnancy andassociated factors of folate supplementation: A cross-sectional study. ClinNutr. 2021 Sep;40(9):5053-5061. doi: 10.1016/j.clnu.2021.01.012.      （IF:7.324）  

6.  Ma Z#, Sun X#, Zhang Y, Li H,Sun D, An Z*, Zhang Y*. Risk of Thromboembolic Events in Cancer PatientsTreated with Immune Checkpoint Inhibitors: A Meta-analysis of RandomizedControlled Trials. Thromb Haemost. 2022 Jun 30. doi: 10.1055/s-0042-1749185.      （IF:6.681）  

7.  Ye Z, Busse JW, Hill MD,Lindsay MP, Guyatt GH, Prasad K, Agarwal A, Beattie C, Beattie J, Dodd C, HeranMKS, Narayan S, Chartúir NN, O'Donnell M, Resmini I,Sacco S, Sylaja PN, Volders D, Wang X, Xie F, Zachrison KS, Zhang L, Zhong H, AnZ*, Smith EE. Endovascular thrombectomy and intravenous alteplase inpatients with acute ischemic stroke due to large vessel occlusion: A clinicalpractice guideline. J Evid Based Med. 2022 Sep;15(3):263-271. doi:10.1111/jebm.12493.        （IF:6.224）  

8.  Du P*, Wang G, Hu T, Li H, AnZ*. Integration Analysis of Pharmacokinetics and Metabolomics to PredictMetabolic Phenotype and Drug Exposure of Remdesivir. Front Pharmacol. 2022 Jan5;12:779135. doi: 10.3389/fphar.2021.779135.    （IF:5.988）

9.   An Z#, Zhao R#, Han F, Sun Y, Liu Y*, Liu L*. Potential Serum BiomarkersAssociated with Premature Rupture of Fetal Membranes in the First Trimester.Front Pharmacol. 2022 Jul 8;13:915935. doi: 10.3389/fphar.2022.915935.     （IF:5.988）

10. Hu T*, Sun Y, An Z*.Dose- and time-dependent manners of moxifloxacin induced liver injury bytargeted metabolomics study. Front Pharmacol. 2022 Sep 16;13:994821. doi:10.3389/fphar.2022.994821.    （IF:5.988）  

11. Wang X, Turhon M, Yang X, LiuJ, Zhang H, Li T, Song D, Zhao Y, Guan S, Maimaitili A, Wang Y, Feng W, Wan J,Mao G, Shi H, An Z*, Wang Y*. Could statin improve outcomes afterpipeline embolization for intracranial aneurysms in a real-world setting? TherAdv Neurol Disord. 2023 May 10;16: 17562864231170517. doi:10.1177/17562864231170517.       （IF:5.9）      

12. Hu T*, Zhang W, Han F, Zhao R,Liu L, An Z*. Plasma fingerprint of free fatty acids and theircorrelations with the traditional cardiac biomarkers in patients with type 2diabetes complicated by coronary heart disease. Front Cardiovasc Med. 2022 Jul22;9:903412. doi: 10.3389/fcvm.2022.903412.     （IF:5.846）  

13. Ren L#, Xuan L#, Li A#, Yang Y,Zhang W, Zhang J, Zhang Y, An Z*. Gamma-aminobutyric acidsupplementation improves olanzapine-induced insulin resistance by inhibitingmacrophage infiltration in mice subcutaneous adipose tissue. Diabetes ObesMetab. 2024 Jul;26(7):2695-2705. doi: 10.1111/dom.15585.    （IF:5.8）      

14. Yang H, Yu X, An Z*.Cutaneous Toxicity Associated With Enfortumab Vedotin: A Real-Word StudyLeveraging U.S. Food and Drug Administration Adverse Event Reporting System.Front Oncol. 2022 Jan 19;11:801199. doi: 10.3389/fonc.2021.801199.   （IF:5.738）

15. Hu Y#, Lu W#, Tang B, Zhao Z*, AnZ*. Urinary incontinence as a possible signal of neuromuscular toxicityduring immune checkpoint inhibitor treatment: Case report and retrospectivepharmacovigilance study. Front Oncol. 2022 Sep 12;12:954468. doi:10.3389/fonc.2022.954468.      （IF:5.738）

16. Zhang Y, Ran L, Liang Y, ZhangY, An Z*. Safety analysis of pemigatinib leveraging the US Food and Drugadministration adverse event reporting system. Front Pharmacol. 2023 Jul24;14:1194545. doi: 10.3389/fphar.2023.1194545.      （IF:5.6）      

17. Yang H, Wang Z, Zhang Y, Xu M,Wang Y, Zhang Y, An Z*, Tong Z*. Effectiveness of inactivated COVID-19vaccines against SARS-CoV-2 Omicron subvariant BF.7 among outpatients inBeijing, China. Vaccine. 2023 Nov 22;41(48):7201-7205. doi:10.1016/j.vaccine.2023.10.036.   （IF:5.5）      

18. Du P*, Xuan L, An Z*,Zhang Y*. Development and validation of a robust and sensitive HPLC-MS/MSmethod for the quantitation of MRTX849 in plasma and its application inpharmacokinetics. Analyst. 2022 Mar 14;147(6):1175-1180. doi:10.1039/d1an01928g.        （IF:5.227)  

19. Cong L†,Wan Z†, Li P†, Liu D, He J*, AnZ*, Liu L. Metabolic, genetic, and pharmacokinetic parameters for theprediction of olanzapine efficacy. Eur J Pharm Sci. 2022 Aug 15:106277. doi:10.1016/j.ejps.2022.106277.     (IF:5.112)

20. Hu T, Zhang W, Han F, Zhao R,Liu H, An Z*. Machine learning reveals serum myristic acid, palmiticacid and heptanoylcarnitine as biomarkers of coronary artery disease risk inpatients with type 2 diabetes mellitus. Clin Chim Acta. 2024 Mar 15;556:117852.doi: 10.1016/j.cca.2024.117852.      (IF:5)  

21. Yang H, Yu X, Hou W, Liu X,Chen J, Zhang Y, Wang Y, Zhu Y, Qian Q, Ma K, An Z*. Effectiveness andsafety of nirmatrelvir-ritonavir in kidney transplant recipients with severekidney dysfunction infected with COVID-19. Antimicrob Agents Chemother. 2024Mar 6;68(3):e0138423. doi: 10.1128/aac.01384-23.    （IF:4.9）      

22. Hu T#, An Z#, Sun Y,Wang X, Du P, Li P, Chi Y*, Liu L*. Longitudinal Pharmacometabonomics forPredicting Malignant Tumor Patient Responses to Anlotinib Therapy: Phenotype,Efficacy, and Toxicity. Front Oncol. 2020 Nov 12;10:548300. doi:10.3389/fonc.2020.548300.      （IF:4.848）  

23. Hu T, Sun Y, Li H, Du P, LiuL*, An Z*. Dual derivatization strategy for the comprehensivequantification and double bond location characterization of fatty acids byultra-high performance liquid chromatography-tandem mass spectrometry. JChromatogr A. 2021 Feb 22;1639:461939. doi: 10.1016/j.chroma.2021.461939.       （IF:4.759）

24. Wang X#, Wang C#, Zhang Y*, AnZ*. Effect of pharmacogenomics testing guiding on clinical outcomes inmajor depressive disorder: a systematic review and meta-analysis of RCT. BMCPsychiatry. 2023 May 12;23(1):334. doi: 10.1186/s12888-023-04756-2.        （IF:4.4）

25. Sun X#, Wang H#, Zhan X, Yan Y,Chen K, An Z*, Zhou H*. Comparison of the safety profiles forpirfenidone and nintedanib: a disproportionality analysis of the US food anddrug administration adverse event reporting system. Front Pharmacol. 2024 May27;15:1256649. doi: 10.3389/fphar.2024.1256649.      （IF:4.4）      

26. Hu T#*, Li H#, Xu B, Du P, LiuL, An Z*. Parallel derivatization strategy for comprehensive profilingof unconjugated and glycine-conjugated bile acids using Ultra-high performanceliquid chromatography-tandem mass spectrometry. J Steroid Biochem Mol Biol.2021 Nov;214:105986. doi: 10.1016/j.jsbmb.2021.105986.        （IF:4.292）

27. Zhang Y#, Ma Z#, Sun X, FengX*, An Z*. Interstitial lung disease in patients treated withCyclin-Dependent Kinase 4/6 inhibitors: A systematic review and meta-analysisof randomized controlled trials. Breast. 2022 Apr;62:162-169. doi:10.1016/j.breast.2022.02.011. （IF:4.254）  

28. Ma Z, Zhang Y, Zhu M, Feng L,Zhang Y*, An Z*. Interstitial lung disease associated with anti-HER2 anti-bodydrug conjugates: results from clinical trials and the WHO's pharmacovigilancedatabase. Expert Rev Clin Pharmacol. 2022 Nov;15(11):1351-1361. doi:10.1080/17512433.2022.2121705.    （IF:4.108）  

29.  Hu T#*, Ren L#, Li H, An Z*.Effects of Vitamin D supplementation or deficiency on metabolic phenotypes inmice of different sexes. J Steroid Biochem Mol Biol. 2023 May;229:106250. doi:10.1016/j.jsbmb.2023.106250.   （IF:4.1）      

30. Wang X#, Zhang Y#, Huang C,Yang H, Jiang C, Yu X, Zhao R, Hong J, Zhang Y, Wang Y, Zhao R, An Z*,Tong Z*. Booster vaccines dose reduced mortality in hospitalized COVID-19patients requiring oxygen supplementation: Evidence from the Beijing Omicronoutbreak. Hum Vaccin Immunother. 2024 Dec 31;20(1):2361500. doi:10.1080/21645515.2024.2361500. Epub 2024 Jun 21.       （IF:4.1）      

31. An Z#, Wang X#, Li P#, He J, Liu L*. Exploring the metaboliccharacteristics and pharmacokinetic variation of paroxetine in healthyvolunteers using a pharmacometabonomic approach. J Pharm Biomed Anal. 2021 Sep10;204:114224. doi: 10.1016/j.jpba.2021.114224.    （IF:3.935）  

32. Zhou H#, Sun X#, Lyu S, Yu X,Li R, Wang H*, An Z*. Evaluation of Tigecycline Utilization and Trendsin Antibacterial Resistance from 2018 to 2021 in a Comprehensive TeachingHospital in China. Infect Drug Resist. 2023 Feb 14;16:879-889. doi:10.2147/IDR.S395158.       （IF:3.9）

33. Zhang J, Han L, Liu H, ZhangH*, An Z*. Metabolomic analysis reveals the metabolic disturbance inaortic dissection: Subtype difference and accurate diagnosis. Nutr MetabCardiovasc Dis. 2023 Aug;33(8):1556-1564. doi: 10.1016/j.numecd.2023.05.006.       （IF:3.9）      

34. Liu H#, Zhao Z#, Wang Y, Liu L,Yang Y, An Z*. Study on the Relationship between Rivaroxaban and FactorXa Activity in Blood Based on HPLC-MS/MS. Curr Drug Metab.2021;22(14):1132-1138. doi: 10.2174/1389200222666211126093627.      （IF:3.731）  

35. Tang B#, Zhang Y#, Wang Y, WangX, An Z*, Yu X*. Effect of bariatric surgery on long-term cardiovascularoutcomes: a systematic review and meta-analysis of population-based cohortstudies. Surg Obes Relat Dis. 2022 May 16:S1550-7289(22)00202-7. doi:10.1016/j.soard.2022.05.007.       （IF:3.709）  

36. Xu M, Ma Z, Feng X, An Z*.Comparison of four criteria for potentially inappropriate medications in olderpatients with newly diagnosed non-small cell lung cancer. Expert Opin Drug Saf.2024 May 22:1-7. doi: 10.1080/14740338.2024.2348567.   （IF:3.6）      

37. Wang X, Luo L, Wang Y, An Z*.Effect of Platelet Function Testing Guidance on Clinical Outcomes for Patientswith Intracranial Aneurysms Undergoing Endovascular Treatment. AJNR Am JNeuroradiol. 2023 Aug;44(8):928-933. doi: 10.3174/ajnr.A7923.        （IF:3.5）      

38. Sun Y, Cong L, Yang S, Zhao R, AnZ*, Liu L*. Moxifloxacin Induced Liver Injury by Causing LachnospiraceaeDeficiency and Interfering with Butyric Acid Production through Gut-Liver Axis.Dis Markers. 2022 Apr 29;2022:9302733. doi: 10.1155/2022/9302733. （IF:3.464）  

39. Hu T#, An Z#, Li H, LiuY, Xia L, Qiu L, Yao A, Ma L*, Liu L*. UHPLC-MS/MS-Based Metabolomics andClinical Phenotypes Analysis Reveal Broad-Scale Perturbations in EarlyPregnancy Related to Gestational Diabetes Mellitus. Dis Markers. 2022 Aug24;2022:4231031. doi: 10.1155/2022/4231031.   （IF:3.464）  

40. Yang H, Zhang Y, Wang Z, Xu M,Wang Y, Zhang Y, Feng X, An Z*. Adherence and recommended optimaltreatment to Azvudine application for the treatment of outpatient COVID-19patients: A real-world retrospective study. Heliyon. 2024 May 4;10(9):e30619.doi: 10.1016/j.heliyon.2024.e30619.       （IF:3.4）      

41. Hu T, Shi C, Liu L, Li P, SunY, An Z*. A single-injection targeted metabolomics profiling method fordetermination of biomarkers to reflect tripterygium glycosides efficacy andtoxicity. Toxicol Appl Pharmacol. 2020 Jan 15;389:114880. doi:10.1016/j.taap.2020.114880.    （IF:3.347）

42. Hu T#, An Z#, Shi C, LiP, Liu L*. A sensitive and efficient method for simultaneous profiling of bileacids and fatty acids by UPLC-MS/MS. J Pharm Biomed Anal. 2020 Jan30;178:112815. doi: 10.1016/j.jpba.2019.112815.    （IF:3.209）  

43. An Z, Hu T, Lv Y, Li P, Liu L*. Targeted amino acid and related aminesanalysis based on iTRAQ®-LC-MS/MS for discovering potential hepatotoxicitybiomarkers. J Pharm Biomed Anal. 2020 Jan 30;178:112812. doi:10.1016/j.jpba.2019.112812. （IF:3.209）  

44. Yang H, Zhang Y, Feng X*, AnZ*. Bleeding Complications in Vancomycin-Induced Thrombocytopenia: AReal-world Postmarketing Pharmacovigilance Analysis. Clin Ther. 2023Sep;45(9):868-872. doi: 10.1016/j.clinthera.2023.06.022.   （IF:3.2）

45. Yang H, Wang Z, Wang C, ZhangY, Han S, An Z*. Cost-effectiveness of Azvudine for High-riskOutpatients with Mild-to-moderate Coronavirus Disease 2019 in China. Clin Ther.2024 Sep;46(9):e1-e5. doi: 10.1016/j.clinthera.2024.07.009.       （IF:3.2）      

46. Liu D#, An Z#, Li P,Chen Y, Zhang R, Liu L*, He J*, Abliz Z. A targeted neurotransmitterquantification and nontargeted metabolic profiling method forpharmacometabolomics analysis of olanzapine by using UPLC-HRMS. RSC Adv. 2020May 13;10(31):18305-18314. doi: 10.1039/d0ra02406f.     （IF:3.119）  

47. Ma Z, Pei J, Zhang Y, Li H, SunD, Zhang Y*, An Z*. Interstitial pneumonitis associated with EGFR/ ALKtyrosine kinase inhibitors used in non-small cell lung cancer: anobservational, retrospective, pharmacovigilance study. Expert Opin Drug Saf.2023 Mar;22(3):237-242. doi: 10.1080/14740338.2022.2110235.        （IF:3.1）

48. Jian Y, Han F, Zhu Y, Geng C,Zhang Y, Wu Y, Leng Y, Chen W, An Z*, Zhu H*. Paired comparisons ofvenetoclax concentration in cerebrospinal fluid, bone marrow, and plasma inacute leukemia patients. Clin Transl Sci. 2024 Sep;17(9):e70006. doi:10.1111/cts.70006.     （IF:3.1）

49. Zhang Y, Ma K, Hou W, Liu X,Chen J, Wang Y, Zhu Y, Qian Q, An Z*, Yang H*. Inappropriate prescribingof Nirmatrelvir/Ritonavir in Solid Organ Transplantation with COVID-19Infection: A Multicenter Retrospective Study. Clin Transl Sci.  （IF:3.1）

50. Li B, Yang S, Ye J, Chu S, ChenN*, An Z*. Flavin-containing monooxygenase 1 deficiency promotesneuroinflammation in dopaminergic neurons in mice. Neurosci Lett. 2021 Nov1;764:136222. doi: 10.1016/j.neulet.2021.136222.      （IF:3.046）

51. Yang H, Ding Z, An Z*. Urinarytract infection following the use of BTK inhibitors: a real-world analysis ofpost-marketing surveillance data. Expert Opin Drug Saf. 2024 Mar;23(3):333-338.doi: 10.1080/14740338.2023.2251376.  （IF:3）  

52. Yang J, Yang H, An Z*.Catatonia related to tacrolimus: a real world pharmacovigilance study of FDAadverse event reporting system (FAERS) database. Expert Opin Drug Saf.Published online August 21, 2024. doi:10.1080/14740338.2024.2393757   （IF:3）

53. Zhang Y#, Ma Z#, Sun X, ZhangY, Zhu M, Zhang S, Feng X, An Z*. Anticancer drug-induced interstitiallung disease: a critical appraisal of clinical practice guidelines andconsensus statements. Expert Opin Drug Saf. 2024 Feb 20:1-9. doi:10.1080/14740338.2024.2315113.   （IF:3）  

54. Wang X, Yang H, An Z*.Tacrolimus related diabetic ketoacidosis and hyperglycaemic hyperosmolarnonketotic syndrome: an observational, retrospective, pharmacovigilance study.Expert Opin Drug Saf. 2024 Aug 19:1-6. doi: 10.1080/14740338.2024.2393278.        （IF:3）

55. An Z, Li C, Lv Y, Li P, Wu C, Liu L*. Metabolomics of Hydrazine-InducedHepatotoxicity in Rats for Discovering Potential Biomarkers. Dis Markers. 2018Apr 10;2018:8473161. doi: 10.1155/2018/8473161.    （IF:2.949）

56. Zhang Y#, Wang X#, Huang C,Yang H, Jiang C, Yu X, Hong J, Zhang Y, Wang Y, Zhao R, An Z*, Tong Z*.Nirmatrelvir-Ritonavir Reduced Mortality in Hospitalized Patients with COVID-19During the Omicron Outbreak: Real-World Evidence from Beijing. Infect DrugResist. 2024 Apr 8;17:1367-1377. doi: 10.2147/IDR.S445826.       （IF:2.9）      

57. Li B, Liu M, Wang Y, Zhang H,Xuan L, Huang K, An Z*. Association of Severe Vitamin D Deficiency withHospitalization in the Previous Year in Hospitalized Exacerbated COPD Patients.Int J Chron Obstruct Pulmon Dis. 2024 Jun 25;19:1471-1478. doi:10.2147/COPD.S461029.   （IF:2.7）

58. Hu T,Han F, An Z*.Comprehensiveprofiling of serum glycosphingolipids to discover the diagnostic biomarkers oflung cancer and uncover the variation of glycosphingolipids network indifferent lung cancer subtypes.Anal Methods.     （IF:2.7）      

59.  An Z*, Sun Y, Shi C, Liu L*. Metabonomic and transcriptomic analyses ofTripterygium glycosides tablet-induced hepatotoxicity in rats. Drug ChemToxicol. 2022 May 23:1-15. doi: 10.1080/01480545.2022.2077360. （IF:2.597）  

60. Hu T#*, Li H#, Liu H, Cong L,Liu L, An Z*. High throughput UHPLC-MS/MS method for the simultaneousquantification of six vitamin D metabolites: application for vitamin Ddetermination in patients after liver or kidney transplantation. Anal Methods.2020 Dec 7;12(46):5591-5600. doi: 10.1039/d0ay01088j.    （IF:2.596）

61. An Z*, Shi C, Li P, Liu L*. Stability of amino acids and related aminesin human serum under different preprocessing and pre-storage conditions basedon iTRAQ®-LC-MS/MS. Biol Open. 2021 Feb 26;10(2):bio055020. doi:10.1242/bio.055020.      （IF:2.422）

62. Wang X, Tang B, Liu Y, Wang X,Wang S, An Z*, Wang H*. Clinical practice guidelines for management ofdual antiplatelet therapy in patients with noncardiac surgery: A criticalappraisal using the AGREE II instrument. J Clin Pharm Ther. 2022May;47(5):652-661. doi: 10.1111/jcpt.13593.   （IF:2.145）  

63. Liu H, Yu X, Hu T, Han F, AnZ*, Zhao R*. Simultaneous determination of four antibiotics in human plasmaby high-performance LC-MS/MS: application to therapeutic drug monitoring.Bioanalysis. 2023 Mar;15(5):269-282. doi: 10.4155/bio-2023-0020. （IF:1.8）

64. Han F, Liu H,Hu T, Li P, ZhaoR, An Z*.Development and validation of a rapid HPLC-MS/MS method forsimultaneous determination of cyclosporine A and tacrolimus in whole blood forroutine therapeutic drug monitoring in organ transplantation.Rapid Commun MassSpectrom.   （IF:1.8）